Tempol improves mitochondrial and neurobehavioral deficits in experimental model of Huntington’s disease
Synapse. 2015 Mar;69(3):128-38. 4-hydroxy tempo (Tempol) improves mitochondrial and neurobehavioral deficits in experimental model of Huntington’s disease. Sandhir R1, Mahajan N, Mehrotra A, Aggarwal A, Sunkaria A. 1Department of Biochemistry, Panjab University, Chandigarh, 160014, Punjab, India. Abstract Mitochondrial dysfunctions have been implicated in the progression of Huntington’s disease (HD). To date, several free radical scavengers […]Take a Tour
Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: Preclinical and clinical outcomes.
Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease Volume 1842, Issue 8, August 2014, pp 1282–1294 Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases Jin H1, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG 1 Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA […]Take a Tour